A phase 1 open label, first in human trial to study safety and tolerability of NK-T cells combined with vvDD: An accelerated dose escalation in multiple tumor types. Dorigo, O., Contag, P., Moser, J., Patel, S., Frohlich, M. W. AMER ASSOC CANCER RESEARCH. 2022

View details for Web of Science ID 000892509502098